Taysha Gene Therapies (TSHA) Tops Q1 EPS by 1c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q1 EPS of ($0.10), $0.01 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $3.41 million versus the consensus estimate of $2.76 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
• Take-Two Interactive (TTWO) Reiterated at Buy by StoneX Ahead of November GTA VI Launch
• Yext, Inc. (YEXT) Tops Q2 EPS by 4c